EAM
CLVS

Eagle Asset Management’s Clovis Oncology, Inc. CLVS Stock Holding History

Eagle Asset Management’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-621,111
Closed -$58.2M – 655
2017
Q2 		$58.2M Buy
+621,111
New +$38M 0.35% 91

Other funds holding CLVS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Eagle Asset Management's CLVS Position: Q3 2017 in Review

Eagle Asset Management sold out of Clovis Oncology, Inc. (CLVS) in Q3 2017, closing a stake of 621,111 shares — an estimated $58.2M sold.

Eagle Asset Management first reported a position in CLVS in Q2 2017 and held it in 1 quarter. The position peaked at $58.2M in Q2 2017. 255 funds tracked by Wall St. Rank hold CLVS as of Q3 2017.

  • Eagle Asset Management reported no remaining Clovis Oncology, Inc. position as of Q3 2017 after selling out during the quarter.
  • Eagle Asset Management sold 621,111 Clovis Oncology, Inc. shares in Q3 2017, an estimated $58.2M.
  • Eagle Asset Management first reported a position in Clovis Oncology, Inc. in Q2 2017 and held it in 1 quarter.
  • Eagle Asset Management's Clovis Oncology, Inc. position peaked at $58.2M in Q2 2017.
  • 255 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q3 2017.

Based on Eagle Asset Management's 13F filing for Q3 2017, filed 9 Nov 2017.